Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) reported on Wednesday that its founded entity biopharmaceutical company Karuna Therapeutics Inc (Nasdaq: KRTX) has won acceptance of its New Drug Application (NDA) for KarXT by the US Food and Drug Administration (FDA).
KarXT, co-invented by PureTech, is aimed at treating schizophrenia in adults.
The Prescription Drug User Fee Act (PDUFA) action date is set for 26 September 2024.
If approved, KarXT, based on the EMERGENT clinical trial data, could mark a groundbreaking pharmacological approach to schizophrenia treatment, representing PureTech's third successful venture from inception to FDA approval.
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI